|
 |
CytarabineThis page contains recent news articles, when available, and an overview of Cytarabine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Cytarabine (when available) Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle. For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia. Mechanism Of Action: Cytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. Although the mechanism of action is not completely understood, it appears that cytarabine acts through the inhibition of DNA polymerase. A limited, but significant, incorporation of cytarabine into both DNA and RNA has also been reported. News Articles on Cytarabine What's New in Acute Myeloid Leukemia - Dec 11, 2009 The usual induction therapy for patients with acute myeloid leukemia (AML) is comprised of an anthracycline plus cytarabine, and standard therapy with ... American Journal of Hemotology and Oncology Sunesis Pharma - From Obscurity To Spotlight - Dec 11, 2009 The results of a phase 1b/2 clinical trial testing Voreloxin in combination with Cytarabine, a widely used chemotherapy, in patients with relapsed or ... RTT News Minimal Residual Disease-directed Therapy Improves Outcomes of Childhood AML - Dec 23, 2009 This protocol included a first induction course of high- or low-dose cytarabine and etoposide. A second induction course consisted of low-dose cytarabine ... Cancer Consultants Sprycel® and Chemotherapy Effective for Ph+ ALL - Dec 10, 2009 These patients were treated with eight cycles of alternating hyperCVAD and high-dose cytarabine and methotrexate plus Sprycel. ... Cancer Consultants Tandem Autologous-Allogeneic Stem Cell Transplants Highly Effective for ... - Dec 23, 2009 Fourteen patients were treated with the BEAC (BCNU, etoposide, cytarabine, cyclophosphamide), and thirteen with BEAM (BCNU, etoposide, cytarabine, ... Cancer Consultants More price cuts for drugs postponed for 2010 - Dec 16, 2009 These drugs include the Amlodipine for hypertension, Atorvastatin for anti-cholesterol, Azithromycin as antibiotic/antibacterial, Cytarabine and Doxorubicin ... ABS CBN News Genzyme's Mozobil shows promise in chemosensitization - Dec 9, 2009 The patients were given Mozobil, and four hours later received the AML combination chemotherapy regimen mitoxantrone, etoposide, and cytarabine (MEC). ... pharmabiz.com Antisoma plc announces positive results from AS1411 trial in kidney cancer but ... - Dec 16, 2009 In May 2009 the company reported positive findings from a randomised phase II trial in which AS1411 was given in combination with high-dose cytarabine to ... Trading Markets (press release) Ð’ 2009 г. ожидаетÑ?Ñ? 7,6%-ный роÑ?Ñ‚ фармрынка Филиппин в меÑ?тной валюте - Dec 29, 2009 который обÑ?зал Ñ?ократить вдвое цену 5-ти жизненно Ñ?амых важных лекарÑ?тв: amlodipine, atorvastatin, azithromycin, cytarabine и doxorubicin. ... ИИА. Ремедиум Sunesis to Present Nonclinical Voreloxin Combination Data at AACR-EORTC-NCI ... - Nov 10, 2009 Voreloxin is Synergistic in In Vitro Combination with Cytarabine and Additive in Combination with Azacitidine, Decitabine and Clofarabine Abstract Number ... CNNMoney.com (press release) Antisoma AGM update and Interim Management Statement - Nov 9, 2009 This trial, called ACCEDE, compares AS1413 plus cytarabine with daunorubicin plus cytarabine, the most common initial treatment for AML. ... CNNMoney.com (press release) Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia - Nov 5, 2009 ...unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML. ... Reuters Sigma-Tau to acquire Enzon specialty pharma unit for $300 million - Nov 10, 2009 DepoCyt, a sustained-release formulation of cytarabine approved for lymphomatous meningitis and the antifungal Abelcet (amphotericin B). ... Pharma Times EntreMed, Inc (ENMD), (PARD), (NGSX), (SNSS), (MYRX), (OXGN), (ISIS), (CADX ... - Nov 13, 2009 ...treated with voreloxin in the company's ongoing Phase 2 clinical study of voreloxin in combination with cytarabine in relapsed or refractory AML. ... Live-PR.com (Pressemitteilung) Antisoma drug wins orphan drug status in the US and EU - Oct 20, 2009 Promising Phase II data - published at the 2008 ASH and 2009 ASCO meetings – showed that adding AS1411 to cytarabine substantially boosted response rates ... Pharma Times Positive FDA News for Nuvo Research (TSX:NRI) and Sunesis (Nasdaq: SNSS) could ... - Nov 5, 2009 ...unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML. ... Small Cap Network Other News To Note - Nov 5, 2009 ...unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML. ... Therapeutics Daily (press release) (registration) Trade Alert: SNSS, SIRI, ONNN - Nov 5, 2009 ...unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML. ... TMCnet Sunesis completes enrollment in Phase II leukemia trial - Nov 3, 2009 ..."Results from Reveal-1 and our ongoing Phase Ib/II trial of voreloxin in combination with cytarabine in relapsed/refractory AML will contribute greatly to ... Trading Markets (press release) Genzyme Reports Third-Quarter Financial Results - Oct 22, 2009 Genzyme is conducting a randomized, placebo-controlled phase 3 trial comparing Clolar in combination with cytarabine to cytarabine alone in relapsed and ... Business Wire (press release) 美 ì‹ ê³„ì—´ í•ì•”ì œ í?¬ê·€ì•½ ì§€ì • - Nov 12, 2009 ...ìœ ë?„ 화학요법으로 효과를 보지 ëª»í• ê³ ë ¹í™˜ìž?를 대ìƒ?으로 2ìƒ? ìž„ìƒ?ì?´ 실시ë?˜ê³ 있으며, 재발·불ì?‘ AML 환ìž?ì—?게ë?„ '시타ë?¼ë¹ˆ'(cytarabine) 병용으로 시험ë?˜ê³ 있다. 디지틀보사 Dubbele chemo redt leukemiepatiënten - Nov 4, 2009 Verdubbeling van het andere medicijn, cytarabine, is wel geprobeerd en dat werkte bij patiënten jonger dan zestig. Voor zestigplussers was het zo giftig dat ... De Standaard ã€?å?¥åº·é†«é»žé?ˆã€‘化療毒性å??應與處置 - Oct 18, 2009 ...常見的個別藥物包括Doxorubicinã€?Cytarabineã€?Docetaxel，以å?ŠFluorouracil。而發生的機率則與劑é‡?有關，包括最高的血ä¸æ¿ƒåº¦å?Šç´¯ç©?的劑é‡?。主è¦?症狀有皮膚疼痛性的 ... 人間福報 High-dose cytarabine and mitoxantrone in consolidation therapy for... - Apr 21, 2005 Correspondence: Dr RF Schlenk, Department of Internal Medicine III, University Hospital of Ulm, Robert-Koch-Strasse 8, 89081 Ulm, Germany. ... Nature.com Ara-C, Cytarabine-U - Nov 26, 2008 Cytarabine is given intravenously. Sometimes it is given as a shot under the skin or directly into the spinal fluid. It can be given in a low, average, ... WebMD Hold on Vion leukemia Phase III clinical trial lifted by the FDA - Jan 8, 2008 The trial studied the effect of Cloretazine in combination with cytarabine in treating relapsed acute myelogenous leukemia. ... Forbes Cytarabine (Systemic).(Drug overview) - May 1, 2006 Cytarabine ( sye-TARE-a-been) belongs to the group of medicines called antimetabolites. It is used to treat some kinds of cancers of the blood. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com … study of altered gene expression after cytarabine resistance in... - Feb 15, 2007 In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 2002; 117: 860–868. | Article | PubMed | ISI | ChemPort | ... Nature.com CYTARABINE LIPOSOME (Intrathecal route) - sye-TARE-a-been LYE-poh … - May 1, 2007 Cytarabine liposome injection should be administered only under the supervision of a qualified physician experienced in the use of intrathecal cancer ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com … myeloid leukemia cells confers cytarabine resistance through MAPK... - Nov 24, 2005 Cytarabine (1-b-D-arabinofuranosyl-cytosine, Ara-C) is the major ... Problems related to resistance to cytarabine in acute myeloid leukemia. ... Nature.com … Cytarabine Demonstrates Benefit Over Cytarabine Alone in Relapsed ... - Jun 13, 2008 By Emma Hitt, PhD. COPENHAGEN, Denmark -- June 13, 2008 -- The novel alkylating agent VNP40101M shows efficacy in combination with cytarabine in patients ... DG News AML patients with Down syndrome have a high cure rate with AML-BFM … - May 26, 2005 4 days and idarubicin 7 mg/m 2 on days 3 and 5; intrathecal cytarabine on days 0 ... The increased in vitro sensitivity to cytarabine and daunorubicin of DS ... Nature.com Vion Initiates Phase I/II Cancer Trial for Cloretazine With Cytarabine... - May 9, 2008 Vion Pharmaceuticals has started an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine in combination with cytarabine ... RedOrbit China issues domestic recall of tainted leukemia drugs - Sep 17, 2007 Most of the drugs involved -- methotrexate and cytarabine hydrochloride -- have been recovered and authorities have traced the remainder, the Xinhua News ... Pay-Per-View - Orlando Sentinel - ProQuest Archiver Cytarabine, Liposomal (Intrathecal). - Jul 28, 2005 Liposomal cytarabine (LIP-oh-som-al sye-TARE-a-been)belongs to the group of medicines known as antineoplastics. It is used to treat cancer of the lymph ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Gene mutation ups leukemia drug's effect - Jun 19, 2008 ..."If confirmed, AML patients in the future will likely be screened for RAS mutations, and those who have one may get high-dose cytarabine for post-remission ... United Press International … Plus Gemcitabine Proves Superior to Methotrexate Plus Cytarabine - Feb 14, 2006 ...of a pralatrexate (PDX)/gemcitabine combination relative to a commonly used combination of methotrexate/cytarabine (ara-C) in treating lymphoma. ... StreetInsider.com - StreetInsider.com (subscription) Long-Acting Cytarabine Prompts Problems in ALL Patients - May 25, 2007 NEW YORK MAY 25, 2007 (Reuters Health) - A substantial proportion of patients with acute lymphocytic leukemia (ALL) who received intrathecal liposomal ... Cancerpage.com UPI NewsTrack Health and Science News - Jun 19, 2008 ..."If confirmed, AML patients in the future will likely be screened for RAS mutations, and those who have one may get high-dose cytarabine for post-remission ... United Press International Chemical in Feverfew Plant May Fight Leukemia - Feb 25, 2005 The drug, called cytarabine, didn't match parthenolide's results. Cytarabine showed "modest toxicity" to the leukemia cells and "relatively high toxicity" ... WebMD … Promise in Combination With Low-Dose Cytarabine for Older Patients... - Jun 21, 2006 AMSTERDAM, THE NETHERLANDS -- June 21, 2006 -- The use of arsenic trioxide (ATO) in combination with low-dose cytarabine (ara-C) shows additive benefits ... DG News Plant Derivative Attacks The Roots Of Leukemia - Mar 3, 2005 In laboratory experiments, they also compared how human leukemia stem cells reacted to parthenolide, versus a common chemotherapy drug called cytarabine. ... sciencedaily.com Antisoma starts phase II trial of AS1411 in acute myeloid leukaemia - Aug 6, 2007 It evaluates addition of AS1411 to the current standard therapy, cytarabine (Ara-C). Patients are being randomly assigned to one of three groups: cytarabine ... marketwire.com Vion to appeal Nasdaq stock delisting - Aug 15, 2008 The company has begun a Phase 1/2 clinical trial of Cloretazine in combination with cytarabine in elderly patients with previously untreated acute ... Bizjournals.com Genzyme Begins Phase 3 Pivotal Study Of Clolar(R) In Adult Acute … - Sep 7, 2006 This trial is evaluating Clolar in combination with cytarabine. Its primary objective is to measure overall response rate in AML and ALL patients 30 years ... Medical News Today - Medical News Today (press release) Seattle Genetics, Celgene strike research deal - Mar 20, 2008 Seattle Genetics is also conducting a study of SGN-33, along with an existing drug, cytarabine, in patients with acute myeloid leukemia. ... Seattle Post-Intelligencer - Seattle Post Intelligencer Clinical characteristics and outcomes in patients with t(8;21) acute ... - Aug 16, 2007 Event-free survival rates with high- and standard-dose cytarabine were shown in (d). ... Among those, 21 patients received high-dose cytarabine-containing ... Nature.com Role of cytokines in the treatment of acute leukemias: a review - Feb 23, 2006 11, 28 Exposure of leukemic cells to growth factors and cytarabine increases ... Cycle 2 consisted of cytarabine 1000 mg/m 2 every 12 h on days 1–6 and ... Nature.com How It Works - Nov 26, 2008 Interferon may be combined with cytarabine or imatinib to treat CML. It can also be used with other drugs to treat melanoma or kidney cancer. ... WebMD … Leukemia; Liposomal daunorubicin and cytarabine are effective as … - Oct 24, 2006 Keywords: Udine, Italy, Reinduction Chemotherapy, Cytarabine, Drug Delivery, Drug Resistance, Encapsulation, Liposomal Daunorubicin, Liposomes, ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Leukemia; Cytarabine-induced fever complicated the clinical course of... - Mar 29, 2005 2005 MAR 29 - (NewsRx.com) -- Cytarabine-induced fever is found to complicate the clinical course of leukemia. Scientists in Turkey conducted a study "to ... Pay-Per-View - Cancer Weekly - Factiva, from Dow Jones Xanthus Completes Special Protocol Assessment with FDA for Phase 3 … - Jun 12, 2007 The Phase 3 trial is designed as an open-label, randomized, active control, multi-center study of Xanafide in combination with cytarabine compared to ... Genetic Engineering News - Genetic Engineering News (press release) Antisoma announces positive interim data from AS1411 phase II trial... - Dec 8, 2008 Cytarabine is given at1.5 g/m² every 12 hours for 4 days (ie a total dose of 12 ... AS1411 infusion isinitiated 3 days before cytarabine treatment so that ... International Business Times Leukemia; Cytarabine-induced fever complicated the clinical course of... - Mar 28, 2005 2005 MAR 28 - (NewsRx.com) -- Cytarabine-induced fever is found to complicate the clinical course of leukemia. Scientists in Turkey conducted a study "to ... Pay-Per-View - Hematology Week - Factiva, from Dow Jones Metabasis Therapeutics Presents Poster at American Society of... - Jun 4, 2006 ..."Cytarabine is a well known chemotherapeutic that is not effective against primary ... By directly delivering an activated form of cytarabine to the liver, ... RedOrbit Antisoma AGM update and Interim Management Statement - Nov 20, 2007 The first report will compare 10 mg/kg/day AS1411 plus cytarabine with cytarabine alone. The primary endpoint is the proportion of patients achieving a ... marketwire.com Leukemia; Cytarabine-induced fever complicated the clinical course of... - Apr 2, 2005 2005 APR 2 - (NewsRx.com) -- Cytarabine-induced fever is found to complicate the clinical course of leukemia. Scientists in Turkey conducted a study "to ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones … Leukemia treated by tetrandrine, daunorubicin, etoposide and cytara... - May 15, 2006 Keywords: Zhenjiang, People's Republic of China, Acute Myeloid Leukemia, Chemotherapy, Clinical Trial, Cytarabine, Drug Resistance, Cancer Drugs, Etoposide, ... Pay-Per-View - Cancer Weekly - Factiva, from Dow Jones Xanthus Initiates Pivotal Phase 3 Trial of Xanafide in Secondary... - Oct 8, 2007 The Phase 3 trial is designed as an open-label, randomized, active control, multi-center study of Xanafide in combination with cytarabine compared to ... Free with registration - Business Wire - AccessMyLibrary.com Sunesis Pharmaceuticals Presents Data from Clinical Trials of... - Jun 16, 2008 ..."We are very pleased by the interim results reported today from our Phase 1b combination study of voreloxin with cytarabine. We look forward to reporting ... Lifescience-online Randomized trial of two therapies for acute lymphocytic leukemia... - May 16, 2005 Patients treated with cytarabine plus high-dose mitoxantrone appeared to have a survival advantage at three, four, and five years. ... eurekalert.org Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia … - Dec 7, 2008 ...for elderly patients with newly diagnosed AML and from its Phase 1b/2 study of voreloxin in combination with cytarabine for relapsed/refractory AML. ... prnewswire.com Vion picks Ben Venue Labs to make anti-cancer drug - Dec 13, 2006 Cloretazine is in a Phase 3 trial in combination with cytarabine in relapsed acute myelogenous leukemia, and a Phase 2 pivotal trial as a single agent in ... Mass High Tech Depocyt Granted Full Approval - Apr 24, 2007 The FDA has granted full approval to Enzon Pharmaceuticals' Depocyt (cytarabine liposome) injection for the treatment of patients with lymphomatous ... Facts and Comparisons Randomized trial of two therapies for acute lymphocytic leukemia... - May 12, 2005 Patients treated with cytarabine plus high-dose mitoxantrone appeared to have a survival advantage at three, four, and five years. ... PsychCentral.com Gene mutation improves leukaemia drug's effect - Jun 20, 2008 But high-dose cytarabine is the better therapy for some patients, and the findings of this study may enable doctors to identify those individuals. ... Science Centric Metabasis' liver cancer drug gets US OD status.(Metabasis Therapeutics... - Sep 17, 2007 The agent is a novel HepDirect pro-drug of cytarabine monophosphate (araCMP) designed to produce the oncolytically-active form, cytarabine triphosphate ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Feverfew compound gets at leukemia roots - Feb 23, 2005 Comparing the impact of parthenolide to the common chemotherapy drug cytarabine, they found that parthenolide selectively killed leukemia cells while ... Wikinews … fluid white cell counts in three patients receiving liposomal... - Jun 5, 2008 Intrathecal depocyte is a formulation of cytarabine, where the active drug is ... A single injection of 50 mg of liposomal cytarabine maintains cytotoxic ... Nature.com Imatinib demonstrates improved survival rates in patients with... - Apr 1, 2007 A total of 382 (69%) of the patients taking imatinib and 16 (3%) of the patients taking interferon alfa plus cytarabine continued their original treatment. ... $9.94 - Formulary - Alacra Store Intensive chemotherapy and autologous hematopoietic stem cell … - Mar 9, 2006 Stem cells were mobilized after the fourth cycle of cytarabine by ... After the second cycle of cytarabine a complete hematological remission (CHR), ... Nature.com Oblimersen Shows Promising Results in Older Patients with Acute … - May 6, 2005 All received treatment with cytarabine, daunomycin and Genasenseâ„¢. Complete remissions occurred in 14 patients (48%). Seven of these 14 patients have ... RxPG NEWS Data Show Encouraging Results for a Potential New Front-Line Treatment... - Jun 2, 2008 Patients also had to be previously untreated and unlikely to benefit from conventional induction chemotherapy (7+3 anthracycline plus cytarabine) based on ... newswise.com Illinois Administrative Code - 77 Ill. Adm. Code 790.2902 CYTARABINE... - Aug 10, 2005 77 Ill. Adm. Code 790.2902 CYTARABINE (Repealed) Repealed. (Source: Repealed at 17 Ill. Reg. 15916, effective September 20, 1993) ... Pay-Per-View - Illinois Administrative Code - Loislaw The outcome of intensive induction therapy in patients 70 years with... - Mar 8, 2007 Of particular note, 264 patients (91%) received uniform induction therapy consisting of daunorubicin 60 mg/m 2 /day 3 days and cytarabine 100 mg/m 2 /day 7 ... Nature.com Intensive consolidation versus oral maintenance therapy in patients... - Jan 26, 2006 6-Thioguanine, cytarabine and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation and either prolonged ... Nature.com Genetic Engineering & Biotechnology News - Biotechnology from Bench … - Sep 22, 2008 After the dose of Cloretazine in combination with daunorubicin and cytarabine is determined in Phase I, the Phase II investigation will determine the ... Genetic Engineering News - Genetic Engineering News (press release) CPX-351 (cytarabine:daunorubicin). - Oct 1, 2008 CPX-351 (cytarabine:daunorubicin) liposome injection (Celator) for the treatment of acute myeloid leukemia Copyright 2008 Advanstar Communications, Inc. $9.94 - Formulary - Alacra Store Celator Pharmaceuticals raises Series C financing of over USD 22.5m. - Jul 29, 2008 The proceeds will be used to fund Phase 2 studies of CPX-351 (a liposomal formulation of cytarabine:daunorubicin) in patients with acute myeloid leukemia. ... $9.94 - M2 Europharma - Alacra Store High-dose chemotherapy with autologous stem cell transplantation as... - Apr 11, 2006 Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS ... Nature.com FDA Approvals: Kadian, Depocyt, Reclast - Jun 12, 2007 On April 19, the FDA granted full approval to cytarabine liposome ... Cytarabine was previously granted accelerated approval by the FDA on the basis of ... Medscape Is there a role for postremission therapy in older adults with acute ... - Jun 9, 2005 The CALGB focuses on giving two courses of high-dose cytarabine and evaluating ... Low-dose cytarabine vs intensive chemotherapy in the treatment of acute ... Nature.com Clinical and biological features of favorable-risk acute myelogenous ... - Feb 3, 2005 In one study from the Cancer and Leukemia Group B, cytarabine intensification ... 15 Finally, in a trial of four cycles of cytarabine-based consolidation ... Nature.com Pediatric acute myeloid leukemia: international progress and future … - Jul 28, 2005 Regarding cytarabine, different schedules are also being used, including lower and ... High-dose cytarabine is likely to contribute to CNS-prophylaxis, ... Nature.com Common 4q24 deletion in four cases of hematopoietic malignancy: early... - May 26, 2005 Despite consolidation cures with idarubicin and cytarabine, followed by high-dose ... Complete remission was obtained by treatment with cytarabine and ... Nature.com Risk factors for invasive aspergillosis in neutropenic patients with ... - Feb 24, 2005 Cycle 1 consisted of cytarabine (200 mg/m 2 given by continuous infusion on days ... Cycle 2 consisted of cytarabine (1000 mg/m 2 iv over a period of 2 h ... Nature.com SkyePharma PLC - Papers On DepoCyt(R) to be Presented at ASCO. - May 31, 2006 DepoCyt(R) is a sustained release injectable formulation of cytarabine and is approved ... Cytarabine is known to be an effective treatment for neoplastic ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Vion Pharmaceuticals Announces FDA Lift of Clinical … - Jan 8, 2008 Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Early findings show promise as AS1411 AML study proceeds to higher- … - Jul 7, 2008 Patients are now being enrolled into the second ("higher dose") stage of the trial, which compares 40 mg/kg/day AS1411 plus cytarabine with cytarabine alone ... Lifescience-online Successive clinical trials for childhood acute myeloid leukemia at St... - Nov 10, 2005 The conditioning regimen consisted of cytarabine, cyclophosphamide, ... The first course of induction with etoposide plus cytarabine yielded a CR rate of ... Nature.com Press Release: Vion Pharmaceuticals Announces Initiation of Clinical ... - May 8, 2008 Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Gemtuzumab therapy for isolated extramedullary AML relapse following ... - Feb 27, 2007 Management Primary leukemia treatment with idarubicin, cytarabine, etoposide, dexamethasone, tioguanine on protocol and salvage therapy with mitoxantrone ... Nature.com Unexpected occurrence of second malignancies in patients treated with... - Jul 14, 2005 Patients included in the IFN-cytarabine group received the same induction ... Interferon and low-dose cytarabine compared with Imatinib for newly diagnosed ... Nature.com Acute myelogenous leukemia in Chile PINDA protocols 87 and 92 results - Mar 17, 2005 Induction ADE chemotherapy: Cytarabine 100 mg/m 2 iv on days 1 and 2, ... Maintenance treatment: Daily thioguanine, 40 mg/m 2 orally, cytarabine 40 mg/m 2 ... Nature.com Large interindividual differences in cellular sensitivity to calicheam... - Jun 19, 2008 No cross-resistance was observed between calicheamicin and cytarabine (=0.11) ... Based on our in vitro data, we suggest combining GO with cytarabine and/or ... Nature.com A phase I study of tipifarnib combined with conventional induction... - Dec 18, 2008 The regimen consisted of cytarabine 100 mg/m 2 /day continuous intravenous (iv) ... As the FTIs can cause a G1 arrest, their combination with cytarabine is ... Nature.com Vion Pharmaceuticals Announces Initiation of Clinical Trial of... - May 8, 2008 Cloretazine(R) (VNP40101M) will be given as a 30 - 60 minute infusion on day 1 approximately 3-4 hours after the start of the cytarabine infusion. ... RedOrbit Gene Mutation Improves Leukemia Drug's Effect - Jun 27, 2008 But high-dose cytarabine is the better therapy for some patients, and the findings of this study may enable doctors to identify those individuals. ... emaxhealth.com Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in … - Dec 6, 2008 ..."In the Phase 1 trial, CPX-351 had a tolerability profile that appears better than conventional cytarabine/daunorubicin treatment and produced impressive ... prnewswire.com Antisoma reports initial AML trial data. - Jul 21, 2008 Among 11 patients who received AS1411 plus cytarabine, one had a complete response (CR) and one had a complete response with incomplete recovery of platelet ... $9.94 - Pharma Marketletter - Alacra Store Acute Myeloid Leukemia; Acute myeloid leukemia patients 50 years of … - Sep 19, 2006 We have previously established the activity of clofarabine plus cytarabine in AML relapse," investigators in the United States reported. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Baby met leukemie heeft nu veel meer kans op genezing - Jul 20, 2007 Vooral het tot voor kort weinig bij zuigelingen gebruikte middel cytarabine scoorde goed. Dit vormt dan ook een hoofdbestanddeel van de nieuwe therapie, ... Trouw Chine: les victimes de médicaments contre la leucémie infectés... - Dec 4, 2007 La SFDA et le ministère de la Santé ont suspendu la production, la vente et l'usage du méthotrexate et de la cytarabine hydrochloride, deux médicaments ... XINHUA Bone cancer treatment ineffective, despite promising laboratory data - Nov 10, 2008 Cytarabine decreases the levels of a certain key protein in Ewing sarcoma ... "Cytarabine is not an effective agent for patients with Ewing sarcoma and this ... eurekalert.org FDA Grants Full Approval for DepoCyt(R) for the Treatment of … - Apr 20, 2007 Lymphomatous meningitis can be controlled with cytarabine, but because of the ... DepoCyt gradually releases cytarabine into the cerebral spinal fluid ... RedOrbit The role of reduced intensity conditioning allogeneic stem cell … - Apr 21, 2005 After diagnosis, patients were included in different institutional protocols and received standard induction chemotherapy with daunorubicin and cytarabine. ... Nature.com Press Release: Sunesis Pharmaceuticals Reports Financial Results for ... - Aug 7, 2008 Phase 1b/2 Study of Voreloxin in Combination with Cytarabine ... from an ongoing Phase ... Phase 1b/2 clinical trial combining voreloxin with cytarabine . ... Pay-Per-View - PR Newswire - HighBeam Research FDA Grants Full Approval for DepoCyt ® for the Treatment of … - Jan 7, 2005 Lymphomatous meningitis can be controlled with cytarabine, but because of the ... DepoCyt gradually releases cytarabine into the cerebral spinal fluid ... businesswire.com Lorus Therapeutics Announces Publication of a Clinical Study … - Jul 2, 2008 All patients in the study received LOR-2040 and high dose cytarabine in therapeutic doses within a dose escalating design, which determined a well-tolerated ... Lifescience-online Granulocytic sarcoma and subsequent acute leukemia recurrence with … - Mar 20, 2006 The patient was treated with a chemotherapy induction scheme 3+7 (idarubicine 12 mg/m 2 , days 1–3 and cytarabine 150 mg/m 2 , days 1–7) obtaining ... Nature.com Steroid-responsive cauda equina syndrome associated with GVHD after … - Nov 12, 2007 Our patient was diagnosed with AML M1 and complete hematological remission was achieved with cytarabine and idarubicine followed by intermediate dose of ... Nature.com Chronic idiopathic myelofibrosis expressing a novel type of TEL... - Nov 23, 2006 Additional two courses of chemotherapy with high-dose cytarabine for consolidation ... Despite the intensive chemotherapy with cytarabine and idarubicin, ... Nature.com High-dose chemotherapy with autologous stem cell transplantation in … - Mar 20, 2006 BEAM regimen consisted of carmustine (300 mg/m 2 iv on day -6), etoposide (200 mg/m 2 twice daily iv on days -5 through -2), cytarabine (200 mg/m 2 twice ... Nature.com AML patients with CEBP mutations mostly retain identical mutant... - Feb 2, 2006 After 1995, the postremission therapy consisted of high-dose cytarabine plus daunomycin alternating with etoposide for 4–6 courses. ... Nature.com Hematopoietic colony-stimulating factor priming does not influence … - Nov 6, 2008 Colony-stimulating factor priming is commonly used in clinical care in at least one chemotherapy regimen, namely fludarabine and cytarabine administered ... Nature.com Chemotherapy Can Be More Toxic To Brain Cells Than To Cancer Cells … - Dec 2, 2006 Cytarabine, which interferes with cell metabolism, is used to treat leukaemia and lymphomas. Dietrich et al.'s results show that clinical concentrations of ... Medical News Today - Medical News Today (press release) Press Release: SkyePharma PLC - Papers On DepoCyt(R) to be … - May 31, 2006 DepoCyt(R) is a sustained release injectable formulation of cytarabine and is approved ... Cytarabine is known to be an effective treatment for neoplastic ... Pay-Per-View - PR Newswire - HighBeam Research Cancer Therapy; Acute myeloid leukemia subcutaneous recombinant … - Sep 5, 2006 ..."Randomized trials of substituting HiDAC for standard dose cytarabine (SDAC) during induction therapy for newly diagnosed AML have not demonstrated an ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Press Release: Lorus announces international conference presentation... - Dec 12, 2005 Lorus announces international conference presentation of the clinical trial of GTI-2040 combined with high-dose Cytarabine in acute myeloid leukemia. from ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti … - Dec 10, 2007 CPX-351 is a liposomal formulation of cytarabine and daunorubicin delivered in a 5:1 molar ratio shown in preclinical studies to represent a synergistic ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Celator(R) Pharmaceuticals Announces Enrollment of … - Nov 18, 2008 CPX-351 is a liposomal formulation of cytarabine and daunorubicin delivered in a 5:1 molar ratio shown in preclinical studies to represent a synergistic ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Lorus Therapeutics Announces Publication of a Clinical... - Jul 2, 2008 2040 with high-dose cytarabine without compromising ... under the symbol LOR, and on the American ... PR Newswire. Article: Lorus Therapeutics presents new ... Pay-Per-View - PR Newswire - HighBeam Research Lorus announces international conference presentation of the clinical... - Dec 12, 2005 Such patients usually have a very low expectation of complete response of approximately 10 to 20 per cent on salvage therapies such as high-dose cytarabine. ... $4.95 - PR Newswire - ECNext Brand Names/Synonyms: Cytarabine is also known by the following brand names and/or synonyms1beta-Arabinofuranasylcytosine; AR3; Ac-1075; Alexan; Ara-C; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabin; Cytarabina; Cytarabine; Cytarabine [USAN:BAN:INN:JAN]; Cytarabinoside; Cytarabinum [INN-Latin]; Cytarbel; Cytosar; Cytosar-U; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; beta-Arabinosylcytosine; beta-Cytosine arabinoside; beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosylcytosine; 1-(beta-D-Arabinofuranosyl)cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinosylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; Cytarabine (JP14/USP); Cytarabine(USAN); Cytosine 1-beta-D-arabinofuranoside; Cytosine arabinoside (VAN); Cytosine beta-D-arabinoside; Cytosine, beta-D-arabinoside; Cytosine, 1-beta-D-arabinosyl-; Cytosine, 1-beta-D-arabinosyl-; Cytosine-beta-D-arabinofuranoside; Cytosine-beta-arabinoside; Cytosine-1-beta-D-arabinofuranoside; Cytosine-beta-D-arabinofuranoside; Depocyt (TN); Depocyt (liposomal); beta-D-Arabinosylcytosine Drug Category: Cytarabine is categorized under the following by the FDA: Immunosuppressive Agents; Antivirals; Antimetabolites; Antineoplastic Agents; ATC:L01BC01 Dosage Forms: injectable solution Absorption: less than 20% of the orally administered dose is absorbed from the gastrointestinal tract Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidin-2-one |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |